Conexiant’s news site is now MDSpire News. Learn more
Advertisement
2026 ASCO Breast Cancer Highlights: PANKU-Breast02
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD, discuss new results from the PANKU-Breast02 study of izalontamab brengitecan (iza-bren), a dual-antibody drug conjugate, in metastatic triple-negative breast cancer.
Interpretation:
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD, discuss the PANKU-Breast02 study.
Limitations:
The provided context does not include the study design, results, or outcome data.
Harold Burstein, MD, PhD, and Jennifer A. Ligibel, MD discuss new research from the Breast Cancer Weight Loss (BWEL) trial, as well as recommendations for lifestyle, diet and GLP1 agonists.
